Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.50 |
| ▸ | HTR2B | P41595 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884874 | 1.00 | HTR2C (0.50) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| SCHEMBL17884835 | 1.00 | HTR2C (0.50) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| SCHEMBL30609697 | 1.00 | HTR2C (0.50) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| SCHEMBL5631509 | 0.88 | HTR2C (0.50) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| SCHEMBL5631516 | 0.88 | HTR2C (0.50) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| SCHEMBL5632222 | 0.88 | HTR2C (0.50) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| Hydrochloric Acid SCHEMBL5632374 | 0.87 | RAD52 (0.52) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| Hydrochloric Acid SCHEMBL5632028 | 0.87 | RAD52 (0.52) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| Hydrochloric Acid SCHEMBL5632022 | 0.87 | RAD52 (0.52) | HTR2CHTR2BHTR2AKCNH2RAD52 | |
| SCHEMBL5631025 | 0.87 | HTR2C (0.51) | HTR2CHTR2BHTR2AKCNH2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2C 2380/4885HTR2B 1760/4885HTR2A 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.